AstraZeneca has announced an immuno-oncology collaboration with US biotech Seres Therapeutics, which will focus on increasing understanding of the gut microbiome in order to increase effica
Eli Lilly has produced phase 3 data that supports use of its Cyramza combined with Roche's Tarceva in first-line non-small cell lung cancer with EGFR mutations, paving the way for filings w
Germany’s Merck KGaA has described 2018 as a “challenging” year, which saw profits hit by currency headwinds and the company struggling to convince shareholders at semiconductor Versum firm
US-based Merck & Co is putting further pressure on its arch-rival Bristol-Myers Squibb with a potential new six-week dosing schedule for some European patients taking its Keytruda (pemb
